ライフサイエンスコーパス: immunodeficiency

1 d cells may thus be central to the described immunodeficiency.

2 fection can be seen in cases with underlying immunodeficiency.

3 defects in POLD1 as a novel cause of T-cell immunodeficiency.

4 s of the nuclear factor-kappaB pathway cause immunodeficiency.

5 thus characterizing the disorder as primary immunodeficiency.

6 first-line tool for the diagnosis of primary immunodeficiency.

7 k, particularly in individuals with previous immunodeficiency.

8 e for a severe, clinically relevant systemic immunodeficiency.

9 o a severe clinical presentation of combined immunodeficiency.

10 toinflammatory disorder, 14 (15%) a combined immunodeficiency, 3 (3%) an innate immune defect, and 2

11 ed in an adult with ectodermal dysplasia and immunodeficiency a germline, gain-of-function mutation,

12 These patients present with immunodeficiency accompanied by severe nonimmunological

13 ut hematopoietic cell transplant, congenital immunodeficiency (adjusted odds ratio, 1.90; 95% CI, 1.2

14 ratio, 3.15; 95% CI, 2.09-4.74), congenital immunodeficiency (adjusted odds ratio, 6.94; 95% CI, 3.8

15 isorders of the blood system such as primary immunodeficiencies and beta-thalassaemia.

16 hown remarkable efficacy in the treatment of immunodeficiencies and cancer.

17 associated with food insecurity can lead to immunodeficiencies and shifts in the microbiome that dri

18 cy in humans, causing clinically significant immunodeficiency and an autoimmune lymphoproliferative s

19 development or function can result in severe immunodeficiency and autoimmunity.

20 reported to be pathogenic in common variable immunodeficiency and glomerulocystic kidney disease.

21 oach to achieving lasting correction of both immunodeficiency and hypoparathyroidism.

22 , with the goal of correcting the underlying immunodeficiency and thrombocytopenia.

23 mophagocytic lymphohistiocytosis, congenital immunodeficiency, and hematopoietic cell transplant are

24 s in the LFA-1-C3-axis contribute to primary immunodeficiency, and identifies intracellular C3 as bio

25 cohorts of patients transplanted for primary immunodeficiency are lacking.

26 NF-kappaB1-related phenotype, which includes immunodeficiency, autoimmunity, autoinflammation, and ca

27 erlying EBV-induced disease in these primary immunodeficiencies but also identified molecules and pat

28 lokathexis (WHIM) syndrome is a rare primary immunodeficiency caused by gain-of-function mutations in

29 within the last 20 yr to correct the T cell immunodeficiency caused by gammac-deficiency (SCID X1) a

30 The human Immunodeficiency Centromeric Instability Facial Anomalie

31 The autosomal recessive immunodeficiency, centromeric instability, and facial an

32 scribe five patients from four families with immunodeficiency coupled with atopy, lymphoproliferation

33 RSF13B [n = 3]) or cause a CVID-like primary immunodeficiency (CTLA4 [n = 2], KMT2D [n = 2], or BIRC4

34 A main feature of common variable immunodeficiency (CVID) is hypogammaglobulinemia (HG).

35 of immune deficiency in 235 common variable immunodeficiency (CVID) patients seen in the United Stat

36 omplication in patients with common variable immunodeficiency (CVID), but the optimal treatment is un

37 demy of Allergy, Asthma & Immunology Primary Immunodeficiency Diseases Committee established a work g

38 anagement of patients with suspected primary immunodeficiency diseases.

39 valuation of patients with suspected primary immunodeficiency diseases.

40 -Aldrich syndrome (WAS), an X-linked primary immunodeficiency disorder (PID) resulting from the defic

41 conditions have been clustered with primary immunodeficiencies in the latest practice parameters; ho

42 eath downstream of FAS and FASL-cause severe immunodeficiency in addition to autoimmune lymphoprolife

43 der cases with severe intestinal atresia and immunodeficiency in cases with complete loss of protein.

44 these functions, and its lack causes severe immunodeficiency in humans.

45 nant for the IgE phenotype but did not cause immunodeficiency in the heterozygous state.

46 in this field provided insights into primary immunodeficiencies, inherited autoimmune and autoinflamm

47 velopment of diabetes in NOD severe combined immunodeficiency mice receiving diabetogenic splenocytes

48 n aggressive tumor growth in severe combined immunodeficiency mice.

49 Notably, despite this profound immunodeficiency, mice chronically infected with CL13 co

50 d after establishment of the Italian Primary Immunodeficiency Network registry (84 months before vs 2

51 lticenter study based on the Italian Primary Immunodeficiency Network registry was established in 200

52 The precise mechanism leading to profound immunodeficiency of HIV-infected patients is still only

53 In five patients we detect a primary immunodeficiency or enteropathy, with clinical consequen

54 lones associated with cell cycle and primary immunodeficiency pathways identifies patients with signi

55 nses(7-12), but the mechanisms that underlie immunodeficiency remain undefined.

56 nic granulomatous disease (CGD) is a primary immunodeficiency resulting in life-threatening infection

57 mined in LNCaP tumor-bearing severe combined immunodeficiency (SCID) mice after sacrifice at defined

58 al study of 878 patients with likely primary immunodeficiency sequenced between 2010 and 2020.

59 Rates of acquired immunodeficiency syndrome (AIDS) or death on suppressive

60 ional Maternal Pediatric Adolescent Acquired Immunodeficiency Syndrome Clinical Trials [IMPAACT] P106

61 l therapeutic target to prevent non-acquired immunodeficiency syndrome events.

62 on-gamma (IFN-gamma) autoantibody-associated immunodeficiency syndrome is not well understood.

63 d-Specific)/Lsh in human DNA causes a severe immunodeficiency syndrome, but the nature of the defect

64 HIV-2, a human pathogen that causes acquired immunodeficiency syndrome, is distinct from the more pre

65 an, suggesting IKBKB K171R underlies a novel immunodeficiency syndrome.

66 Immunodeficiency syndromes (acquired/congenital/iatrogen

67 Patients with primary immunodeficiencies undergoing allogeneic hematopoietic c

68 hrough newborn screening for severe combined immunodeficiency using the T-cell receptor excision circ

69 ect on LDL-C Lowering in SubJEcts with Human Immunodeficiency VirRus and INcreased Cardiovascular Ris

70 monitoring on 2489 people living with human immunodeficiency virus (age >=15 years).

71 those of humans with cytomegalovirus, human immunodeficiency virus (even when under antiretroviral t

72 as identified in the p2 region of the feline immunodeficiency virus (FIV) Gag protein.

73 For unknown reasons, the feline immunodeficiency virus (FIV), which infects both domesti

74 ne is an effective means of decreasing human immunodeficiency virus (HIV) acquisition among women.

75 e been implicated in increased risk of human immunodeficiency virus (HIV) acquisition, but whether th

76 taining contraceptives and the risk of human immunodeficiency virus (HIV) acquisition.

77 ignificantly increase the incidence of human immunodeficiency virus (HIV) acquisition.

78 An outbreak of human immunodeficiency virus (HIV) among people who inject dru

79 rate the central nervous system during human immunodeficiency virus (HIV) and cryptococcal meningitis

80 rapy has transformed the management of human immunodeficiency virus (HIV) and hepatitis C (HCV) coinf

81 We assessed prevalence of testing for human immunodeficiency virus (HIV) and hepatitis C virus (HCV)

82 ch associated with the pathogenesis of human immunodeficiency virus (HIV) and hepatitis C virus .

83 e is frequent among people living with human immunodeficiency virus (HIV) and is associated with redu

84 nflammation in adults living with both human immunodeficiency virus (HIV) and tuberculosis (TB), but

85 Multiple factors influence the human immunodeficiency virus (HIV) antibody response produced

86 d with hepatitis B virus (HBV) and the human immunodeficiency virus (HIV) are at risk of developing h

87 ed fibrosis in hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infected patients receiv

88 We further tested the effect of human immunodeficiency virus (HIV) coinfection on diagnostic p

89 itical barrier to the development of a human immunodeficiency virus (HIV) cure is the lack of a scala

90 Annual human immunodeficiency virus (HIV) diagnoses in the United Sta

91 idelines recommend genotype testing at human immunodeficiency virus (HIV) diagnosis ("baseline genoty

92 ltimorbidity (MM) according to year of human immunodeficiency virus (HIV) diagnosis in elderly people

93 Advanced human immunodeficiency virus (HIV) disease (CD4 count < 200 ce

94 Human immunodeficiency virus (HIV) drug resistance profiles ar

95 The human immunodeficiency virus (HIV) epidemic among adolescent g

96 The human immunodeficiency virus (HIV) epidemic in India is concen

97 The ongoing spread of human immunodeficiency virus (HIV) has driven novel interventi

98 Human immunodeficiency virus (HIV) imparts increased heart fai

99 ons may be an effective way to prevent human immunodeficiency virus (HIV) in adolescent girls and you

100 th and renal impairment in people with human immunodeficiency virus (HIV) in resource-limited setting

101 V) drugs are highly active against the human immunodeficiency virus (HIV) in the body compartment, th

102 s of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virolog

103 cause of morbidity and mortality among Human Immunodeficiency virus (HIV) infected patients; however

104 ty and morbidity in people living with human immunodeficiency virus (HIV) infection (PLWH).

105 Human immunodeficiency virus (HIV) infection and antiretrovira

106 ontributes to immune activation during human immunodeficiency virus (HIV) infection and is usually as

107 in sub-Saharan Africa are at risk for human immunodeficiency virus (HIV) infection and unintended pr

108 the incidence of rectal gonorrhea and human immunodeficiency virus (HIV) infection in men who have s

109 at among people living with late-stage human immunodeficiency virus (HIV) infection initiating antire

110 rimoxazole preventive therapy (CPT) in human immunodeficiency virus (HIV) infection is a World Health

111 revious studies suggest that untreated human immunodeficiency virus (HIV) infection is associated wit

112 Human immunodeficiency virus (HIV) infection is characterized

113 It is unclear whether human immunodeficiency virus (HIV) infection results in perman

114 Identification of nonviral markers of human immunodeficiency virus (HIV) infection that increase bef

115 h as, diabetes, organ transplantation, Human immunodeficiency virus (HIV) infection, and elevated ser

116 ng global infectious diseases, such as human immunodeficiency virus (HIV) infection, malaria and infl

117 aharan Africa, often in the context of human immunodeficiency virus (HIV) infection.

118 re built for patients with and without human immunodeficiency virus (HIV) infection.

119 ophylaxis (PrEP) for the prevention of human immunodeficiency virus (HIV) infection.

120 adelphia identified an outbreak of new human immunodeficiency virus (HIV) infections among persons wh

121 se management during the past decades, human immunodeficiency virus (HIV) infections are still respon

122 However, the impact on transmission of human immunodeficiency virus (HIV) is uncertain.

123 Human immunodeficiency virus (HIV) may affect the risk of deat

124 Mother-to-child transmission of human immunodeficiency virus (HIV) occurs in the setting of ma

125 asing injection drug use (IDU)-related human immunodeficiency virus (HIV) outbreaks, particularly in

126 , particularly in the absence of known human immunodeficiency virus (HIV) outbreaks.

127 ed 2007-2017 medical records data from Human Immunodeficiency Virus (HIV) Outpatient Study (HOPS) par

128 Identifying where human immunodeficiency virus (HIV) persists in people living w

129 Human immunodeficiency virus (HIV) persists indefinitely in in

130 naX mRNA and the gag-pol transcript of Human Immunodeficiency Virus (HIV) perturb translation elongat

131 troviral therapy (ART), CD4+ count and human immunodeficiency virus (HIV) plasma viral load (PVL) on

132 Human immunodeficiency virus (HIV) pre-exposure prophylaxis (P

133 the feasibility of daily and nondaily human immunodeficiency virus (HIV) preexposure prophylaxis (Pr

134 Human immunodeficiency virus (HIV) prevention interventions fo

135 The primary human immunodeficiency virus (HIV) reservoir is composed of re

136 Despite low plasma human immunodeficiency virus (HIV) RNA, HIV controllers have e

137 old, in Montreal, we compared observed human immunodeficiency virus (HIV) seroconcordance in previous

138 We estimated the time from human immunodeficiency virus (HIV) seroconversion to antiretro

139 <1 year, 1-4 years, adults), site, and human immunodeficiency virus (HIV) status (adults only) were c

140 cted controls and investigated whether human immunodeficiency virus (HIV) status is independently ass

141 We aimed to determine whether human immunodeficiency virus (HIV) status was independently as

142 Among the patients in whom human immunodeficiency virus (HIV) status was known, 38% of th

143 rent and future NCD burden in Kenya by human immunodeficiency virus (HIV) status.

144 ic to the VS.IMPORTANCE The lentivirus human immunodeficiency virus (HIV) targets and destroys CD4(+)

145 Human immunodeficiency virus (HIV) testing and early diagnosis

146 have made it possible for persons with human immunodeficiency virus (HIV) to live a near expected lif

147 Although mother-to-child human immunodeficiency virus (HIV) transmission has dramatical

148 n chronic inflammation associated with human immunodeficiency virus (HIV) type 1.

149 iral load testing within 6 months when human immunodeficiency virus (HIV) viral loads exceed 1,000 co

150 ive inflammation in people living with human immunodeficiency virus (HIV) who have pulmonary tubercul

151 ses, occurring in patients living with human immunodeficiency virus (HIV) who were on antiretroviral

152 y for the syndemic of opioid overdose, human immunodeficiency virus (HIV), and hepatitis C virus (HCV

153 ation, violence, alcohol and drug use, human immunodeficiency virus (HIV), and stigma and discriminat

154 tiation rates among people living with human immunodeficiency virus (HIV), and then examined who was

155 sted for antiviral effects against the human immunodeficiency virus (HIV), followed by a comprehensiv

156 ully protective vaccines, particularly human immunodeficiency virus (HIV), malaria and tuberculosis.

157 In human immunodeficiency virus (HIV), the relative contribution

158 y responses, have been shown to be key human immunodeficiency virus (HIV)-1 reservoirs.

159 HAART), lung disease remains common in human immunodeficiency virus (HIV)-infected (HIV+) adolescents

160 al therapy (cART)-treated, perinatally human immunodeficiency virus (HIV)-infected adolescents (PHIV+

161 Studies in human immunodeficiency virus (HIV)-infected individuals sugges

162 In 65 MSM, including 57 human immunodeficiency virus (HIV)-infected men with KS, multi

163 Data from 1802 human immunodeficiency virus (HIV)-negative children aged 1-59

164 data with new data from a prospective human immunodeficiency virus (HIV)-negative UK cohort of 333 t

165 We aimed to identify a human immunodeficiency virus (HIV)-related microbiota signatur

166 rates of liver injury among cotreated human immunodeficiency virus (HIV)-TB coinfected patients were

167 ing 30 elite controllers (ECs), and 30 human immunodeficiency virus (HIV)-uninfected controls were as

168 al outcomes among patients living with human immunodeficiency virus (HIV).

169 in low-income communities affected by human immunodeficiency virus (HIV).

170 ed 200,000 people who have undiagnosed human immunodeficiency virus (HIV).

171 reasingly recognized in people without human immunodeficiency virus (HIV).

172 e male and 70.4% were co-infected with human immunodeficiency virus (HIV).

173 encing mother-to-child transmission of human immunodeficiency virus (HIV).

174 isproportionately impact patients with human immunodeficiency virus (HIV).

175 eutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV).

176 but generally younger population with human immunodeficiency virus (HIV).

177 ofile data supporting its success with human immunodeficiency virus (HIV).

178 eatment-experienced adults living with human immunodeficiency virus (HIV).

179 uberculosis (TB) in people living with human immunodeficiency virus (HIV).

180 detecting p24 antigen as a marker for human immunodeficiency virus (HIV).

181 ommon malignancy in people living with human immunodeficiency virus (HIV)/AIDS.

182 ct on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is u

183 Chronic inflammation in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coi

184 People living with human immunodeficiency virus (HIV+) have greater risk for sudd

185 sful in controlling the replication of Human Immunodeficiency Virus (HIV-1) in many patients, current

186 r weight gain among people living with human immunodeficiency virus (HIV; PLWH) starting efavirenz-ba

187 c variability among people living with human immunodeficiency virus (HIV; PLWH), but remains unexplor

188 ment (NCI) in aging people living with human immunodeficiency virus (PLHIV) and people not living wit

189 People living with human immunodeficiency virus (PLHIV) are at increased risk of

190 syndrome (IRIS) in people living with human immunodeficiency virus (PLHIV) is rarely reported.This s

191 with enrichment for people living with human immunodeficiency virus (PLHIV), within 72 hours of intak

192 Although people living with human immunodeficiency virus (PLWH) are at increased risk of i

193 People living with human immunodeficiency virus (PLWH) are commonly excluded from

194 gically suppressed persons living with human immunodeficiency virus (PLWH) switched from older antire

195 Patients living with human immunodeficiency virus (PLWH) with low CD4 counts are at

196 overrepresented in People Living with Human Immunodeficiency Virus (PLWH).

197 tive impairment in persons living with human immunodeficiency virus (PLWH).

198 ion is common among people living with human immunodeficiency virus (PLWH).

199 an observational study of persons with human immunodeficiency virus (PWH) and uninfected controls, IL

200 ribing trends among people living with human immunodeficiency virus (PWH) are not well described.

201 People with human immunodeficiency virus (PWH) demonstrate increased ather

202 Persons with human immunodeficiency virus (PWH) with persistently low CD4 c

203 irst cause of morbidity in people with human immunodeficiency virus (PWH).

204 Simian-human immunodeficiency virus (SHIV) infection of rhesus monkey

205 e and one pivotal experiment in simian-human immunodeficiency virus (SHIV)-infected rhesus macaques,

206 A robust simian-human immunodeficiency virus (SHIV)-macaque model of latency i

207 l of intrarectal challenge with simian/human immunodeficiency virus (SHIV).

208 mmunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV).

209 nodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) acquisition in humans and m

210 m macaques infected with a mixture of simian immunodeficiency virus (SIV) and simian-human immunodefi

211 drophobic residues typically found in simian immunodeficiency virus (SIV) Env to improve rhesus CD4 b

212 mployed a barcoded synthetic swarm of simian immunodeficiency virus (SIV) in rhesus macaques to inves

213 rded as the main source of latent HIV/simian immunodeficiency virus (SIV) infection of adult humans a

214 Cs) located in the colon secondary to simian immunodeficiency virus (SIV) infection.

215 ur approach was to deliver the entire simian immunodeficiency virus (SIV) proteome by serial vaccinat

216 s are necessary for immune control of simian immunodeficiency virus (SIV).

217 we performed a comprehensive study of simian immunodeficiency virus (SIV)/SHIV-infected infant rhesus

218 Women living with human immunodeficiency virus (WLHIV) have disproportionately h

219 ations in hair among women living with human immunodeficiency virus (WLHIV) in the United States.

220 Human immunodeficiency virus 1 (HIV-1) is a life-threatening p

221 Human immunodeficiency virus 1 (HIV-1) is a retrovirus with a

222 s ac4C to RNAs, have been subverted by human immunodeficiency virus 1 (HIV-1) to increase viral gene

223 Human immunodeficiency virus 1 (HIV-1), the retroviral agent o

224 CD4(+) T cells latently infected with human immunodeficiency virus 1 (HIV-1).

225 The majority of cells with latent human immunodeficiency virus 1 infection are located in lympho

226 cute respiratory syndrome coronavirus, human immunodeficiency virus 1, hepatitis C virus, and Japanes

227 landscape for the surface proteins of human immunodeficiency virus and hepatitis C virus.

228 hinder efforts to end the intertwined human immunodeficiency virus and opioid overdose epidemics.

229 cohort study, one-half of adults with human immunodeficiency virus and pulmonary tuberculosis experi

230 tcomes is not really known outside the human immunodeficiency virus co-infection setting.

231 Using partially validated data from a human immunodeficiency virus cohort, we illustrate the calcula

232 ivation of latent infection following simian immunodeficiency virus coinfection.

233 epatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; exclud

234 We estimated human immunodeficiency virus incidence and incidence rate rati

235 in injury induced by acute simian (or human) immunodeficiency virus infection may persist or spontane

236 Human immunodeficiency virus infection was also associated wit

237 Is) were the first drugs used to treat human immunodeficiency virus infection, and their use can caus

238 hronic inflammatory diseases including human immunodeficiency virus infection, psoriasis, rheumatoid

239 In persons living with human immunodeficiency virus infection, such neuroprotective t

240 The human immunodeficiency virus interacts with the cluster of dif

241 ith diabetes at baseline, those with a human immunodeficiency virus or hepatitis B virus coinfection,

242 Human immunodeficiency virus pre-exposure prophylaxis (PrEP) c

243 stingly, primer extension assays using human immunodeficiency virus reverse transcriptase (HIV-RT) an

244 Ms) (n = 13) were infected with simian/human immunodeficiency virus SHIV.C.CH505.375H.dCT, and triple

245 Using the rhesus macaque simian immunodeficiency virus SIVmac251 model, we can compare p

246 50 to 8000 Hz included weekly AG dose, human immunodeficiency virus status with CD4 count, age, serum

247 Human immunodeficiency virus testing data revealed an increasi

248 oviral therapy (ART) during home-based human immunodeficiency virus testing improved engagement in ca

249 The human immunodeficiency virus type 1 (HIV-1) accessory protein

250 rst innate immune cells that encounter human immunodeficiency virus type 1 (HIV-1) after sexual conta

251 accine provided modest protection from human immunodeficiency virus type 1 (HIV-1) and simian immunod

252 the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1) and vesicular stom

253 The human immunodeficiency virus type 1 (HIV-1) capsid (CA) protei

254 Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) continues to cause

255 The "shock-and-kill" human immunodeficiency virus type 1 (HIV-1) cure strategy invo

256 Complex retroviruses like human immunodeficiency virus type 1 (HIV-1) encode the viral i

257 Millions are exposed to the human immunodeficiency virus type 1 (HIV-1) every year, but no

258 Human immunodeficiency virus type 1 (HIV-1) exploits a number

259 Human immunodeficiency virus type 1 (HIV-1) infection persists

260 tion for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but pro

261 h contradictory data about its role in human immunodeficiency virus type 1 (HIV-1) infection.

262 may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.

263 Envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) is an important ta

264 Establishment of persistent human immunodeficiency virus type 1 (HIV-1) reservoirs occurs

265 icipants: baseline CD4 count, baseline human immunodeficiency virus type 1 (HIV-1) RNA, and CYP2B6 me

266 is an important preclinical model for human immunodeficiency virus type 1 (HIV-1) vaccines, therapeu

267 Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) via breastfeeding

268 ment of therapeutic strategies against human immunodeficiency virus type 1 (HIV-1), but their assembl

269 a virus (EIAV), and the Nef protein of human immunodeficiency virus type 1 (HIV-1).

270 Here, we show that human immunodeficiency virus type-1 (HIV-1) with HBV-associate

271 cardiovascular diseases in people with human immunodeficiency virus who were exposed to darunavir (DR

272 TB were enrolled (47% female; 32% with human immunodeficiency virus).

273 sex with men (for men), infection with human immunodeficiency virus, and injection drug use.

274 s, syphilis, gonorrhea, chlamydia, and human immunodeficiency virus, as well as elevated blood lead l

275 ptor 5 (CCR5) is a key drug target for human immunodeficiency virus, cancer, and inflammation.

276 with an immunocompromising condition (human immunodeficiency virus, diabetes, or malnutrition) were

277 hly treatment-experienced persons with human immunodeficiency virus, extensive antiretroviral drug re

278 eles from divergent clades of HIV and simian immunodeficiency virus, including from primary patient i

279 al human-pathogenic viruses, including human immunodeficiency virus, influenza A virus, and yellow fe

280 ted viruses including cytomegalovirus, human immunodeficiency virus, influenza virus, and dengue viru

281 pear to retain modest activity against human immunodeficiency virus-1 with these mutations possibly a

282 Human immunodeficiency virus-2 infection represents a unique n

283 We used Mycobacterium tuberculosis/simian immunodeficiency virus-coinfected (M. tuberculosis/SIV-c

284 Human immunodeficiency virus-infected children had significant

285 tantially reduce mortality rates among human immunodeficiency virus-infected persons in Africa.

286 antiretroviral therapy (ART)-treated simian immunodeficiency virus-infected rhesus macaques (RMs) un

287 i sarcoma is the most common cancer in human immunodeficiency virus-positive individuals and is cause

288 d treatment, of whom 77% (n = 23) were human immunodeficiency virus-positive, 47% (n = 14) had ever i

289 in immunocompromised patients without human immunodeficiency virus.

290 est study of cardiovascular disease in human immunodeficiency virus.

291 (FTC) 200 mg among adults living with human immunodeficiency virus.

292 key populations also at high risk for human immunodeficiency virus.

293 that enhance the viral infectivity of human immunodeficiency virus.

294 gnant and postpartum women living with human immunodeficiency virus; however the relative contributio

295 The immunodeficiency was marked by a pronounced actin polyme

296 MKL1 deficiency, leading to a novel primary immunodeficiency, was identified.

297 spectively studied 502 children with primary immunodeficiency who were transplanted at our center bet

298 ause reticular dysgenesis, a severe combined immunodeficiency with agranulocytosis, lymphopenia, and

299 n patients with a recessive form of combined immunodeficiency with defects in T, B, and NK cell activ

300 erpes zoster (HZ) include increasing age and immunodeficiency, yet estimates of HZ risk by immunocomp